Sacubitril/Valsartan vs ACE Inhibitors or ARBs: A Systematic Review and Meta-Analysis of Randomized Trials.

ABSTRACT:

Background

Sacubitril/valsartan (SAV) is crucial for managing heart failure (HF). Randomized clinical trials have shown SAV's superiority over angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) in reducing N-terminal pro-B-type natriuretic peptide levels. However, results for cardiovascular (CV) mortality, HF rehospitalization, and all-cause mortality have been mixed.

Objectives

This study aimed to determine hard endpoints among the population with HF treated with SAV vs ACEI/ARBs and conduct a comprehensive risk-benefit analysis of the safety profile for SAV vs ACEI/ARB.

Methods

We queried PubMed, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials for randomized clinical trials from inception to November 2023.

SUBMITTER: Evbayekha E 

PROVIDER: S-EPMC11883387 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature